Allurion Technologies, Inc. · OTC:ALUR
Allurion Technologies — IPO Roadshow (June 2024)
24 slides from Allurion Technologies's IPO roadshow presentation, Jun 26, 2024
Slide 1: Investor Presentation
Exhibit 99.1 Investor Presentation
Slide 2: Disclaimer
1 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this “presentation”) contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the “Company” or “us”) and is provided to the recipients (“you”) of thi
Slide 3: Disclaimer (Continued)
2 Disclaimer (Continued) This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended (the “Securities Act”), and is intended solely for investors that are “qualified institutional buyers” as defined in Rule 144A under the Securities Act, or instituti
Slide 4: Transaction Summary
3 Transaction Summary Issuer Allurion Technologies, Inc. Ticker (Listing) ALUR (NYSE) (1) Offering Amount $20.0 million (100% primary); includes common stock and warrants Warrants will be immediately exercisable at an exercise price equal to the offer price and will expire five years from the Warran
Slide 5: Investment Highlights
4 Investment Highlights Allurion is well-positioned for growth in 2024 and beyond 1 Large addressable market that is continuing to grow; $54B obesity treatment market expected by 2030 Innovative gastric balloon technology that drives durable total body weight loss (14% with one balloon and 23% with
Slide 6: Obesity Is A Significant Problem With Society-Wide Health And Economic Ramifications
5 Obesity Is A Significant Problem With Society-Wide Health And Economic Ramifications Massive market opportunity with $54B revenue opportunity by 2030 The Problem The Opportunity 60 50 40 30 20 10 0 2024 2025 2026 2027 2028 2029 2030 US revenues Ex-US revenues $54B obesity treatment market expected
Slide 7: Other Weight-Loss Therapies
6 Other Weight-Loss Therapies Bariatric surgical procedures and other existing balloons have notable shortcomings Flawed Poor High Poor Go-To-Market Experience Risks Economics Limited Channels Execution Lack of post- Invasive All-in costs for Existing approach Previous procedure patient procedures a
Slide 8: We believe the Allurion balloon solves shortcomings of other treatments
We believe the Allurion balloon solves shortcomings of other treatments The world’s first and only Procedureless™ weight loss device A breakthrough in simplicity 1* Procedureless – swallowed in 15-minute office visit without surgery, endoscopy, or anesthesia Unintrusive – ~4 months after placement,
Slide 9: The Allurion Balloon Is Paired With The Virtual Care Suite
8 The Allurion Balloon Is Paired With The Virtual Care Suite Allurion Allurion Patient App Connected Scale 3 Tracks weight and Analyzes data, body composition, provides real-time empowering and insights, enables enabling patients to sharing with care reach their goals Allurion team, and syncs with t
Slide 10: Comprehensive Clinical Data Supports The Allurion Balloon’s Efficacy Profile
9 Comprehensive Clinical Data Supports The Allurion Balloon’s Efficacy Profile Allurion Balloon Led to 96% of Weight Loss Sequential Allurion Treatment 1 2 3 15% Weight Loss in Just 4 Months Maintained After 1 Year Led to 23% Weight Loss After two sequential balloons, % TBWL ≥30% was Weight Loss ach
Slide 11: The Allurion Balloon Can Also Impact Co-morbidities, Including Diabetes
10 The Allurion Balloon Can Also Impact Co-morbidities, Including Diabetes 1 Positive Early Clinical Results In Diabetic / Pre-diabetic Patients The Allurion Balloon Can Impact Co-morbidities In a study of 518 patients (225 w. diabetes / 293 w. pre-diabetes), majority In 115 patients treated with th
Slide 12: The Allurion Balloon Was Designed To Be Safer Than Alternatives
11 The Allurion Balloon Was Designed To Be Safer Than Alternatives Allurion Results Demonstrate Tolerance Compared to Other Balloons, The Allurion Balloon Thanks To A Unique Design Results In Fewer Serious Adverse Events (SAEs) Device- or procedure-related SAE rates 10.0% Conforms to the shape of th
Slide 13: Large Opportunity in Existing and Future Markets
12 2 Billion Adults Globally with BMI 25+: Large Opportunity in Existing and Future Markets UK Canada Italy Currently launched in 50+ countries that represent France USA Spain 40% of BMI 25+ China Population Mexico UAE India U.S. and China represent Brazil 46% Pre-2022 Launches of BMI 25+ Saudi 2022
Slide 14: Commercial Performance
13 Commercial Performance Allurion’s innovative technology has enabled deep penetration into international markets At a Glance Historical Financials and Procedural Volume 2024 Outlook Revenue ($ in millions) Gross Margin (%) 2023 YoY revenue impacted by Strong management track record macroeconomic h
Slide 15: Macroeconomic And De-stocking Headwinds Are Abating In 24
14 Macroeconomic And De-stocking Headwinds Are Abating In 2024 Procedure volume reflects health of underlying demand and is Q1 results showed growth in revenue and procedure volumes indicative of higher revenue run-rate Quarterly revenue ($M) New App Users (NAU) Quarterly revenue ($M) $13.9 ~22% ~14
Slide 16: US Opportunity
15 US Opportunity Our market research indicates that the US market is large and attractive US Market Opportunity 100% Total population of the US 342 million Target ages (18-76) and 28.1% target BMI (30-40) $18B 96.2 million US TAM* 21.7% Target household income 74.3 million 17.1% Bothered by their w
Slide 17: US Opportunity: AUDACITY trial data expected by year-end 2024
16 US Opportunity AUDACITY trial enrollment completed in Fall 2023, and data is expected by year-end 2024 W0 W16 W24 W40 W48 Balloon 1 Break Balloon 2 Break Moderate Intensity Lifestyle Therapy Treatment Group (n = 250) Moderate Intensity Lifestyle Therapy Control Group (n = 250) Co-Primary 50% resp
Slide 18: Previous Open-Label Balloon Studies Have Shown Significant Weight Loss In the Treatment Group
17 Previous Open-Label Balloon Studies Have Shown Significant Weight Loss In the Treatment Group Open Label Studies Sham Controlled Studies Weight Loss Results from pivotal, open-label (% TBWL) -6.9 -11.6 -3.2 -3.5 balloon studies show higher weight loss in the treatment group and similar weight los
Slide 19: Virtual Care Suite
18 Virtual Care Suite VCS software commercialization is an incremental revenue opportunity Commercialization Opportunity Early Strategic Partnerships Germany's largest weight loss clinic chain with 18 locations worldwide VCS including AI-powered 2,000+ patients on-boarded in coaching 2023 and renewe
Slide 20: Impact of GLP-1s and Allurion’s Opportunity
19 Impact of GLP-1s and Allurion’s Opportunity ~25% of patients tried prescription weight-loss drugs before starting the Allurion Program GLP-1s have several drawbacks… …that have created new opportunities for Allurion 45% of Allurion providers Poor Experience believed anti-obesity medications boost
Slide 21: The Allurion Program Is Anchored By An Innovative Medical Device And Enhanced By The VCS
20 The Allurion Program Is Anchored By An Innovative Medical Device And Enhanced By The VCS GLP-1 drugs have risen in popularity, however… Sustainable weight loss often requires Provider economics matter behavioral change Allurion helps providers alleviate both issues The Allurion Program supports s
Slide 22: Strategic Priorities
21 Strategic Priorities Looking to 2024 and beyond, Allurion will focus on sustainable growth and profitability Invest strategically across key Broaden global presence and markets to drive procedure 1 2 expand into the US market* growth Scale and monetize VCS in Strengthen gross margin and parallel
Slide 23: Future Catalysts
22 Future Catalysts There are several catalysts that could deliver additional upside Reimbursement New Treatment 8-Month Allurion Expansion of Digital Medtronic Strategic Markets Indications Balloon Solutions Partnership Expand reimbursement Recent studies Development of an 8- Supporting further Exp
Slide 24: Allurion
Allurion